Welcome to our dedicated page for Azitra news (Ticker: AZTR), a resource for investors and traders seeking the latest updates and insights on Azitra stock.
Azitra, Inc. (NYSE American: AZTR) is a clinical stage biopharmaceutical company developing therapies for precision dermatology, and its news flow reflects the progress and challenges of an emerging biotechnology issuer. Company announcements frequently highlight updates on its lead program, ATR-12, which uses an engineered strain of Staphylococcus epidermidis to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. News items also cover milestones for ATR-04, an engineered S. epidermidis program for EGFR inhibitor (EGFRi)–associated rash and skin toxicity, and ATR-01, a preclinical program designed to treat ichthyosis vulgaris through filaggrin secretion.
Investors following AZTR news can expect regular coverage of clinical trial milestones, such as initiation of Phase 1b and Phase 1/2 studies, first-patient-dosed events, and the presentation of preclinical and clinical data at scientific and investor conferences. The company’s releases describe participation in events like BIO-Europe, Biotech Showcase, and investment conferences, where management discusses safety data, pharmacology results, and development strategy for ATR-12, ATR-04, and ATR-01.
News about Azitra also includes regulatory and listing developments, including notices from NYSE American regarding compliance with continued listing standards and acceptance of the company’s plan to regain compliance by a specified deadline. Additional articles cover capital markets activity, such as private placements, equity line of credit transactions, and related registration statements and proxy proposals tied to share issuances and warrants.
By monitoring this AZTR news page, readers can track how Azitra advances its live biotherapeutic and engineered protein programs in dermatology, how it responds to stock exchange compliance requirements, and how it structures financings to support ongoing clinical and preclinical work.
Azitra, a clinical-stage biopharmaceutical company, will present at the 2024 BIO International Convention in San Diego. The presentation, scheduled for June 5 at 12:00 PM PDT, will be led by COO Travis Whitfill. Key updates will include progress on ATR-12 for Netherton syndrome and ATR-04 for EGFR inhibitor-induced dermal toxicity. The event runs from June 3-6, 2024.
Azitra (NYSE American: AZTR), a clinical-stage biopharmaceutical company, announced positive preclinical data for ATR-04, aimed at treating EGFR inhibitor-induced dermal toxicity. This condition affects about 150,000 patients in the US. The data, presented at the Society of Investigative Dermatology 2024 Annual Meeting, showed ATR-04 reducing methicillin-resistant S. aureus (MRSA) by 99% in ex vivo pig skin and reducing the pro-inflammatory cytokine IL-36γ by 75% in treated human skin models. Additionally, ATR-04 increased human beta defensin 18-fold compared to the vehicle in human skin models. These results support an upcoming IND application to the FDA for a Phase 1b trial in patients undergoing EGFR inhibitors with dermal toxicity.
Azitra, Inc. announces positive preclinical data of ATR-12 and clinical design in Netherton Syndrome presented at the ASGCT Annual Meeting. ATR-12 inhibits key protease driving Netherton syndrome, delivers LEKTI more effectively than topical application, reduces pro-inflammatory cytokine IL-36g, is safe in minipigs, and shows promising results for a Phase 1b study. The study aims to evaluate safety, efficacy, and skin pharmacokinetics of ATR-12 in Netherton syndrome patients.
Azitra, Inc. (NYSE American: AZTR) reported financial results for Q1 2024, showcasing advancement in clinical trials and pre-IND meetings. The company strengthened its IP portfolio, completed a public offering, and progressed in partnership discussions. With a focus on dermatology treatments, Azitra aims to revolutionize severe skin condition treatments, delivering value to shareholders. Financially, the company saw an increase in R&D and G&A expenses, with a net loss of $2.9 million for Q1 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.